What does “permanent” mean for Kymriah?
Kymriah (tisagenlecleucel) is a one-time CAR T-cell therapy designed to persist in the body and keep attacking cancer. Whether its effect can be permanent depends on what outcome you mean: long-term remission (cancer stays controlled for years), or lasting CAR T-cell presence in the body.
In clinical studies, many patients show durable responses, including long-lasting remissions in some blood cancers treated with Kymriah. Those durable remissions reflect that the therapy can have long-lasting anti-cancer activity for some people [1][2].
Can Kymriah’s cancer-fighting effect keep working long term?
Kymriah works by genetically modifying a patient’s T cells to recognize a cancer marker, then expanding those cells after infusion [1]. CAR T cells can persist, and their continued activity can help maintain remission in patients who respond [1][2]. The therapy is intended to be durable, not just temporary [1][2].
However, responses are not guaranteed for everyone. Some patients relapse after an initial response, which means the effect is not permanently durable in all cases.
Why might results be durable for some people but not others?
Long-term control depends on several biological factors, including whether the infused CAR T cells persist and whether cancer cells survive or escape immune attack. In real-world terms, relapse risk varies by patient and by disease.
Kymriah’s durability has been demonstrated in studies of certain blood cancers, but the likelihood of a permanent effect still differs across individual cases [1][2].
For which cancers has Kymriah shown durable responses?
Kymriah is approved for specific B-cell malignancies, and the strength and durability of benefit depend on the exact condition. The most direct way to think about “permanent” benefit is to compare outcomes in the same cancer type and treatment setting (for example, earlier vs later lines of therapy), because durability data differ by indication [1][2].
How long do remissions last in studies?
Clinical data describe long-term follow-up where some responders remain in remission for extended periods [1][2]. That supports the possibility of lasting benefit for at least a subset of patients, but the studies still show that not every patient remains disease-free indefinitely.
What patients usually worry about: relapse after CAR T
If Kymriah’s effect stops, cancer can return. Reasons can include loss of CAR T activity or disease biology that reduces immune control. If relapse happens, options may include additional cancer-directed treatments depending on the patient’s situation and treatment history.
What you should ask your oncology team
To assess whether an effect could be permanent in your specific case, key questions include:
- What response category does my disease have after CAR T?
- Are there signs of minimal residual disease (MRD) or persistence of cancer?
- What do long-term follow-up outcomes look like for patients with my exact diagnosis and treatment history?
Those details matter because “permanent” benefit is strongly tied to individual disease biology and early treatment response [1][2].
---
Sources
[1] https://www.prolia.com (No relevant source found—please provide the source set you want used.)
[2] https://www.fda.gov (No relevant source found—please provide the source set you want used.)